American Association for Cancer Research shared highlights from the AACR Annual Meeting 2026 on X:
“We congratulate the recipients of the AACR Early-Career Scholar in the Field of Cancer Research Award and welcome them to the AACR Annual Meeting 2026.”
“Cancer survivor and patient advocate Jill Feldman receives the AACR Distinguished Patient Advocacy and Engagement Award during the Opening Ceremony at the AACR Annual Meeting 2026.”
“Anthony Letai addresses the cancer research community during the Opening Ceremony at the AACR Annual Meeting 2026.”
“Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally – The Opening Plenary Session of AACR26 is chaired by Paul Mischel and Alice Shaw.”
“AACR Fellows and Past President Charles L. Sawyers discusses ‘How Cancer Cells Escape Targeted Therapy by Changing Identity’ during the Opening Plenary Session at AACR26.”
“Beyond Blood: The Evolution of CAR T Therapy for Solid Malignancies— AACR Fellows Carl H. June addresses this topic in the Opening Plenary Session at AACR26.”
“The moderator of today’s press conference is Jayesh Desai from Peter MacCallum Cancer Centre.”
“Next-generation KRAS G12C inhibitor elicited promising response rates in patients with advanced lung cancer according to phase I results presented at AACR26 by Byoung Chul Cho. Responses to elisrasib were seen both in patients who were naïve for KRAS G12C inhibitor therapy and in those whose disease progressed on prior KRAS G12C inhibitors.”
“Chemical Rewiring of Biological Circuits for Cancer Therapy: Targeted Protein Degradation and Beyond-Georg E. Winter explores this topic during the AACR26 Opening Plenary Session.”
“The KRAS inhibitor zoldonrasib showed effective and durable responses in patients with previously treated G12D-mutated non-small cell lung cancer, according to updated results from a phase I clinical trial reported at AACR26 by Jonathan W. Riess. Zoldonrasib treatment led to an objective response rate of 52%, a disease control rate of 93%, and a favorable safety and tolerability profile.”
“Rethinking Cancer Diagnosis and Treatment with AI: From Molecular Mechanisms to Clinical Management – Regina Barzilay discusses this topic in the Opening Plenary Session of the AACR Annual Meeting 2026.” 
“An investigational antibody-drug conjugate benefited patients with advanced, platinum-resistant ovarian cancer according to results from a phase I clinical trial presented at AACR26 by Tao Zhu. The antibody-drug conjugate, known as QLS5132, induced an objective response rate of 52.9% and a disease control rate of 100% in 17 evaluable patients who received a dose of at least 3.2 mg/kg.”
“Congratulations to the AACR Trailblazer Cancer Research Grants recipients, supported by Pfizer Inc. AACR’s largest-ever grant program has awarded 15 early-stage and mid-career investigators $1million each to establish novel, highly creative research projects.”
“New Drugs on the Horizon, Part 1: AACRCICR chair Lori S. Friedman and Lawrence G. Hamann chaired the first session in this three-part series that presents first disclosures of the chemical structures of novel agents against emerging cancer targets.”
“New Drugs on the Horizon, Part 2: Danette L. Daniels and Monica Schenone chaired the second session in this three-part series that presents first disclosures of the chemical structures of novel agents against emerging cancer targets.”
“AACR Associate Members engaged in a series of 15-minute one-on-one Personalized Career Conversations with mentors from across the cancer research community during a AACR26 session organized by AACRAMC, AACRMICR, AACRWICR, and the AACR Science Education Committee.”
“Mapping the Molecular Landscape of Head and Neck Cancer to Inform Pan-Tumor Targeting: AACR President Lillian L. Siu delivered her Presidential Address at the AACR Annual Meeting 2026.”
“AACR Foundation President Steve Ryan and AACR CEO Margaret Foti honored Amazon Web Services during the AACR26 Partners in Progress Reception. The AWS IMAGINE ‘Go Further, Faster’ Award supports innovative, technology-driven initiatives such as AACR Project GENIE.”
“Day 3 of AACR26 showcased the latest advances from across the cancer research continuum-including two clinical trials plenary sessions on New Frontiers in Precision Oncology and Therapeutic Advances in ADCs.”
“The moderator of today’s press conference is Ecaterina E. Dumbrava from The University of Texas MD Anderson Cancer Center.”
“BCMA-directed CAR T-cell therapy may be effective against high-risk smoldering myeloma, according to results from the phase II CAR-PRISM trial reported by Omar Nadeem at AACR26. One infusion of ciltacabtagene autoleucel led to minimal residual disease negativity in all patients, and there were no progressions to active myeloma during the median 15.3 months of follow-up.”
“A machine learning model analyzing CpG-based DNA methylation accurately predicted the origin of cancers of unknown primary, according to a presentation at AACR26 by Marco A. De Velasco. This approach may eventually help guide personalized treatment decisions for patients diagnosed with these cancers, De Velasco noted.”
“A deep learning pathomics platform called Path-IO applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in lung cancer patients, according to a study presented at AACR26 by Rukhmini Bandyopadhyay. Path-IO represents the first deep learning-based pathomics biomarker rigorously validated across international real-world cohorts and a phase III randomized clinical trial, said Bandyopadhyay.”
“Jakob Nikolas Kather chaired today’s AACR26 Plenary Session on ‘The AI Revolution in Cancer Research,’ featuring Jure Leskovec, Bo Wang, Suchi Saria, and Faisal Mahmood.”
“Last night, AACR CEO Margaret Foti welcomed the Victoria’s Secret Global Fund for Women’s Cancers and Pelotonia to a special reception to celebrate the AACR‘s ongoing collaboration with these organizations to drive progress against women’s cancers.”
